Merck & Company, Incorporated (MRK)
Email Confirmation
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME
Overview
News
People
Financials
Company Information
Richard T. Clark, CEO/President/Director/Chairman of the Board
One Merck Drive
P. O. Box 100
Whitehouse Station, NJ 08889-0100
US
Map it ![]()
Phone: (908) 423-1000
Fax: (908) 735-1253
Latest news from Portfolio
-
Merck's Latest HeadacheFeb 07 2008
-
A Big Name in Generic DrugsMay 14 2007
-
Merck's Wild RideApr 13 2007
-
Setback for Merck on F.D.A. RulingApr 12 2007
Overview
A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health.
Portfolio Articles
-
Merck's Latest Headache
The drug company, reeling from nine-figure settlements for Vioxx, Vytorin, and Zetia, agrees to stump up another $650 million in a new case.Feb 07 2008 -
A Big Name in Generic Drugs
Mylan expands its reach in the fast-growing market for off-patent pharmaceuticals with a $6.7 billion deal.May 14 2007 -
Merck's Wild Ride
An upbeat earnings forecast and a legal victory overshadow potentially crushing regulatory news on Merck's latest drug.
Apr 13 2007 -
Setback for Merck on F.D.A. Ruling
A government panel rejects Merck's Arcoxia drug, the latest version of its ill-fated Vioxx.
Apr 12 2007
News Feeds
-
Drugmakers in the Dow fall with the overall market
AP
Oct 06 2008
-
Pharmaceutical shares dip after bailout passes
AP
Oct 03 2008
-
Merck ends obesity drug study and regulatory plan
AP
Oct 02 2008
-
Florida sues Merck to recover money spent on Vioxx
AP
Oct 01 2008
-
Drugmakers see mixed results for shares in Q3
AP
Sep 30 2008
-
Merck licenses osteoporosis drug candidate
AP
Sep 25 2008
-
Merck to contract out some sales jobs _ after cuts
AP
Sep 22 2008
-
Brazil to make AIDS drug after Merck talks fail
AP
Sep 18 2008
-
U.S. Merck's Japan unit to slash sales branches
Reuters
Sep 17 2008
-
New Merck osteoporosis drug boosts bone density
AP
Sep 16 2008
Portfolio Blogs
-
Easing the Pain for Some Vioxx Lawyers
Nov 14 2007
Press Releases
-
Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team Oct-02-2008, 09:00AM EDT
-
Merck Discontinues Development of Investigational Medicine Taranabant for Obesity Oct-02-2008, 08:00AM EDT
-
Merck Serono Among the Winners in the German BioPharma Strategy Competition Oct-01-2008, 11:16AM EDT
-
Inotek Appoints Paul G. Howes as President and CEO Oct-01-2008, 10:00AM EDT
News From Around the Web
News
-
Drugmakers in the Dow fall with the overall market
(Boston Globe)Oct 06 2008 -
Icahn Wins Blue Ribbon in ImClone Race (IMCL, LLY, BMY, MRK)
(24/7 Wall St.)Oct 06 2008 -
Is It Time to Run and Hide?
(Motley Fool)Oct 06 2008 -
Merck Discontinues Development Of Investigational Medicine Taranabant For Obesity
(Medical News Today)Oct 06 2008 -
Merck stops development of obesity drug taranabant
(Courier-Post Online, New Jersey)Oct 05 2008 -
State sues Merck for deceptive marketing of Vioxx
(BizJournals)Oct 04 2008 -
Merck pulls plug on obesity drug
(BizJournals)Oct 04 2008 -
Pharmaceutical shares dip after bailout passes
(Boston Globe)Oct 03 2008
Blogs
-
Election bets: Advisors vote on McCain and Obama stocks
(Blogging Stocks)Oct 03 2008 -
Merck pull taranabant
(PharmaGossip)Oct 02 2008
Employees
Number of Employees: 59,800
Revenue per Employee: $399,983
Top Executives
Wendy L. Yarno, Other Executive Officer
Stefan Oschmann, President, Geographical
J. Chris Scalet, Chief Information Officer/Executive VP, Divisional
Dr.Mirian M. Graddick-Weir, Executive VP, Divisional
Bruce N. Kuhlik, Executive VP/General Counsel
Kenneth C. Frazier, Executive VP/President, Divisional
Margaret G. McGlynn, Divisional President
Willie A. Deese, Executive VP/President, Divisional
Peter N. Kellogg, Executive VP/CFO
Adele D. Ambrose, Vice President/Other Executive Officer
Mark E. Mcdonough, Treasurer/Vice President
Adam H. Schechter, President, Divisional
Celia A. Colbert, Senior VP/Secretary
David W. Anstice, Executive VP, Divisional
Peter S. Kim, Divisional President/Executive VP
Board of Directors
Dr. Samuel O. Thier, M.D., Director
Dr. Johnnetta B. Cole, Ph.D., Director
William B. Harrison, Jr., Director
Mark E. Mcdonough, Treasurer/Vice President
Peter C. Wendell, Director
Rochelle B. Lazarus, Director
Wendell P. Weeks, Director
Celia A. Colbert, Senior VP/Secretary
Dr.Thomas E. Shenk, Ph.D., Director
Financials
Quarterly
Annual
| Income Statement | 08/2008 | 02/2008 | 10/2007 | 07/2007 |
|---|---|---|---|---|
| Sales | 847 Mil. | 1.05 Bil. | 1.03 Bil. | 1.05 Bil. |
| Gross Operating Profit | 4.98 Bil. | 5.2 Bil. | 5.05 Bil. | 5.06 Bil. |
| Operating Income before D & A (EBITDA) | 2.04 Bil. | 2.1 Bil. | 1.65 Bil. | 1.94 Bil. |
| Total Income Before Interest Expenses (EBIT) | 4.52 Bil. | -3.06 Bil. | 2.19 Bil. | 2.37 Bil. |
| Total Net Income | 3.3 Bil. | -1.63 Bil. | 1.53 Bil. | 1.68 Bil. |
| Basic EPS, Total | 1.53 | -0.75 | 0.7 | 0.77 |
| Diluted EPS, Total | 1.52 | -0.75 | 0.7 | 0.77 |
| BALANCE STATEMENT | 08/2008 | 02/2008 | 10/2007 | 07/2007 |
|---|---|---|---|---|
| Cash and Equivalents | 6.29 Bil. | 5.34 Bil. | 5.21 Bil. | 3.47 Bil. |
| Total Assets | 17.05 Bil. | 15.05 Bil. | 14.16 Bil. | 12.44 Bil. |
| Total Liabilities | 9.8 Bil. | 12.26 Bil. | 10.51 Bil. | 10.28 Bil. |
| Total Capitalization | 23.49 Bil. | 22.1 Bil. | 24.6 Bil. | 23.61 Bil. |
| Cash Flow | 08/2008 | 02/2008 | 10/2007 | 07/2007 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | 2.53 Bil. | 7 Bil. | 4.65 Bil. | 1.63 Bil. |
| Net Cash From Investing Activities | 1.9 Bil. | -2.81 Bil. | -1.96 Bil. | -1.89 Bil. |
| Net Cash From Financing Activities | -3.58 Bil. | -4.87 Bil. | -3.47 Bil. | -2.21 Bil. |
| Net Change in Cash & Cash Equivalents | 953.3 Mil. | -578.6 Mil. | -706.4 Mil. | -2.45 Bil. |
| Income Statement | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Sales | 4.15 Bil. | 3.73 Bil. | 3.44 Bil. | 3.51 Bil. |
| Gross Operating Profit | 20.05 Bil. | 18.9 Bil. | 18.57 Bil. | 19.43 Bil. |
| Operating Income before D & A (EBITDA) | 7.61 Bil. | 5.96 Bil. | 7.57 Bil. | 8.07 Bil. |
| Total Income Before Interest Expenses (EBIT) | 3.88 Bil. | 6.72 Bil. | 7.87 Bil. | 8.42 Bil. |
| Total Net Income | 3.28 Bil. | 4.43 Bil. | 4.63 Bil. | 5.81 Bil. |
| Basic EPS, Total | 1.51 | 2.04 | 2.11 | 2.62 |
| Diluted EPS, Total | 1.49 | 2.03 | 2.1 | 2.61 |
| BALANCE STATEMENT | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Cash and Equivalents | 5.34 Bil. | 5.91 Bil. | 9.59 Bil. | 2.88 Bil. |
| Total Assets | 15.05 Bil. | 15.23 Bil. | 21.05 Bil. | 13.48 Bil. |
| Total Liabilities | 12.26 Bil. | 12.72 Bil. | 13.3 Bil. | 11.74 Bil. |
| Total Capitalization | 22.1 Bil. | 23.11 Bil. | 23.04 Bil. | 21.98 Bil. |
| Cash Flow | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|
| Net Cash From Continuing Operations | 7 Bil. | 6.77 Bil. | 7.61 Bil. | 8.8 Bil. |
| Net Cash From Investing Activities | -2.81 Bil. | -4.88 Bil. | 2.27 Bil. | -1.64 Bil. |
| Net Cash From Financing Activities | -4.87 Bil. | -5.6 Bil. | -3.04 Bil. | -5.59 Bil. |
| Net Change in Cash & Cash Equivalents | -578.6 Mil. | -3.67 Bil. | 6.71 Bil. | 1.68 Bil. |
Related Companies by Market Cap
Company Name
Price
Change
Market Cap
109.87 Bil.
115.31 Bil.
85.73 Bil.
129.5 Bil.
Company Profile Change Request
The data provided in our company profiles comes from third party information providers.- To request a change please click here
Also in Portfolio.com
Most Read
Most Emailed
Recently Commented
TOP 5
(Daily)
A smart take on the top stories shaping the business world.
Executives & Careers
(Tuesdays)
A weekly guide to the personalities and ideas that are transforming the business world.
Inside Portfolio.com
(Wednesdays)
Our roundup of the week's best from Portfolio.com.
Culture & Lifestyle
(Fridays)
A weekly guide to the best ways to spend your time - and money.
In This Issue
(Monthly)
Be the first to know when the latest issue of Condé Nast Portfolio magazine is online.





